AbbVie
ABBV
1,957 hedge funds and large institutions have $101B invested in AbbVie in 2018 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 741 increasing their positions, 880 reducing their positions, and 94 closing their positions.
2.99% more ownership
Funds ownership: 67.58% → 70.57% (+3%)
2% more capital invested
Capital invested by funds: $99.1B → $101B (+$2.02B)
2% less funds holding
Funds holding: 1,997 → 1,957 (-40)
16% less repeat investments, than reductions
Existing positions increased: 741 | Existing positions reduced: 880
20% less funds holding in top 10
Funds holding in top 10: 128 → 103 (-25)
27% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 94
31% less call options, than puts
Call options by funds: $897M | Put options by funds: $1.3B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.9B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$1.03B |
| 3 |
State Street
Boston,
Massachusetts
|
+$256M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$149M |
| 5 |
N
Natixis
Paris,
France
|
+$145M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$1.67B |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$277M |
| 3 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
-$185M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$169M |
| 5 |
Two Sigma Investments
New York
|
-$127M |
ABBV Hedge Fund Activity: Q3 2018 in Review
1,957 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2018, worth a combined $101B — up 2% from $99.1B a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of ABBV and 69 opened new positions — a net loss of 25 holders — while 880 trimmed existing stakes and 741 added.
The largest buyer was Capital International Investors, adding an estimated $1.9B. The largest seller was Capital Research Global Investors, cutting an estimated $1.67B.
- 1,957 institutional investors held AbbVie (ABBV) as of Q3 2018, down from 1,997 in Q2 2018.
- Funds reported $101B of AbbVie stock for Q3 2018, up 2% quarter-over-quarter.
- 69 funds opened new AbbVie positions in Q3 2018 and 94 closed out, a net change of -25 holders.
- The largest AbbVie buyer in Q3 2018 was Capital International Investors, an estimated $1.9B added.
- The largest AbbVie seller in Q3 2018 was Capital Research Global Investors, an estimated $1.67B sold.
Based on aggregated 13F filings for Q3 2018.